APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Alpha 1 Antitrypsin Deficiency Treatment

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

Selected research

Market Outlook & Growth Opportunities

Global Alpha 1 Antitrypsin Deficiency Treatment Market Outlook and Growth Opportunities 2026

Report ID 173962190429 December 2025198 pages

Choose your research edition.

Industry ResearchAlpha 1 Antitrypsin Deficiency Treatment Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Alpha 1 Antitrypsin Deficiency Treatment Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Alpha 1 Antitrypsin Deficiency Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Alpha 1 Antitrypsin Deficiency Treatment Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Alpha 1 Antitrypsin Deficiency Treatment Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

Global players of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring and Kamada Ltd, etc. Top five players occupy for share about 28%. United States is the largest market, with a share about 37%, followed by European Union and China. In terms of product, Augmentation Therapy is the largest segment, with a share over 44%.

This report provides an overview of the global Alpha 1 Antitrypsin Deficiency Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Alpha 1 Antitrypsin Deficiency Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Alpha 1 Antitrypsin Deficiency Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Alpha 1 Antitrypsin Deficiency Treatment market.

Alpha 1 Antitrypsin Deficiency Treatment Segment by Company

Pfizer

GlaxoSmithKline

AstraZeneca

Boehringer Ingelheim

Teva Pharmaceutical Industries

Takeda

Baxter

Grifols

CSL Behring

Kamada Ltd

Chiesi Pharmaceuticals

Kedrion Group

Vertex Pharmaceuticals

ProMetic Life Sciences

Alpha 1 Antitrypsin Deficiency Treatment Segment by Indication

Augmentation Therapy

Cystic Fibrosis(CF)

Non-CF Bronchiectasis(NCFB)

Diabetes

Other

Alpha 1 Antitrypsin Deficiency Treatment Segment by End Users

COPD

Cystic Fibrosis(CF)

Non-CF Bronchiectasis(NCFB)

Diabetes

Alpha 1 Antitrypsin Deficiency Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Alpha 1 Antitrypsin Deficiency Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Alpha 1 Antitrypsin Deficiency Treatment key companies, revenue, market share, and recent developments.

3. To split the Alpha 1 Antitrypsin Deficiency Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Alpha 1 Antitrypsin Deficiency Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Alpha 1 Antitrypsin Deficiency Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Alpha 1 Antitrypsin Deficiency Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha 1 Antitrypsin Deficiency Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Alpha 1 Antitrypsin Deficiency Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha 1 Antitrypsin Deficiency Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Alpha 1 Antitrypsin Deficiency Treatment industry.

Chapter 3: Detailed analysis of Alpha 1 Antitrypsin Deficiency Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Alpha 1 Antitrypsin Deficiency Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Alpha 1 Antitrypsin Deficiency Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Alpha 1 Antitrypsin Deficiency Treatment Industry Trends Table 2. Alpha 1 Antitrypsin Deficiency Treatment Industry Drivers Table 3. Alpha 1 Antitrypsin Deficiency Treatment Industry Opportunities and Challenges Table 4. Alpha 1 Antitrypsin Deficiency Treatment Industry Restraints Table 5. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Company (2021-2026) Table 7. Global Alpha 1 Antitrypsin Deficiency Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Alpha 1 Antitrypsin Deficiency Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Alpha 1 Antitrypsin Deficiency Treatment Company, Product Type & Application Table 10. Global Alpha 1 Antitrypsin Deficiency Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Alpha 1 Antitrypsin Deficiency Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Augmentation Therapy Table 15. Significant Companies of Cystic Fibrosis(CF) Table 16. Significant Companies of Non-CF Bronchiectasis(NCFB) Table 17. Significant Companies of Diabetes Table 18. Significant Companies of Other Table 19. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type (2021-2026) Table 23. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type (2027-2032) Table 24. Significant Companies of COPD Table 25. Significant Companies of Cystic Fibrosis(CF) Table 26. Significant Companies of Non-CF Bronchiectasis(NCFB) Table 27. Significant Companies of Diabetes Table 28. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application (2021-2026) Table 32. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application (2027-2032) Table 33. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Region (2021-2026) Table 36. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Region (2027-2032) Table 38. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Market Share by Country (2021-2026) Table 41. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Market Share by Country (2027-2032) Table 43. Pfizer Company Information Table 44. Pfizer Business Overview Table 45. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 47. Pfizer Recent Development Table 48. GlaxoSmithKline Company Information Table 49. GlaxoSmithKline Business Overview Table 50. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 52. GlaxoSmithKline Recent Development Table 53. AstraZeneca Company Information Table 54. AstraZeneca Business Overview Table 55. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 57. AstraZeneca Recent Development Table 58. Boehringer Ingelheim Company Information Table 59. Boehringer Ingelheim Business Overview Table 60. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 62. Boehringer Ingelheim Recent Development Table 63. Teva Pharmaceutical Industries Company Information Table 64. Teva Pharmaceutical Industries Business Overview Table 65. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 67. Teva Pharmaceutical Industries Recent Development Table 68. Takeda Company Information Table 69. Takeda Business Overview Table 70. Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 72. Takeda Recent Development Table 73. Baxter Company Information Table 74. Baxter Business Overview Table 75. Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 77. Baxter Recent Development Table 78. Grifols Company Information Table 79. Grifols Business Overview Table 80. Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 82. Grifols Recent Development Table 83. CSL Behring Company Information Table 84. CSL Behring Business Overview Table 85. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 87. CSL Behring Recent Development Table 88. Kamada Ltd Company Information Table 89. Kamada Ltd Business Overview Table 90. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 92. Kamada Ltd Recent Development Table 93. Chiesi Pharmaceuticals Company Information Table 94. Chiesi Pharmaceuticals Business Overview Table 95. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Sales (Kiloton), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 96. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 97. Chiesi Pharmaceuticals Recent Development Table 98. Kedrion Group Company Information Table 99. Kedrion Group Business Overview Table 100. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Sales (Kiloton), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 101. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 102. Kedrion Group Recent Development Table 103. Vertex Pharmaceuticals Company Information Table 104. Vertex Pharmaceuticals Business Overview Table 105. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Sales (Kiloton), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 106. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 107. Vertex Pharmaceuticals Recent Development Table 108. ProMetic Life Sciences Company Information Table 109. ProMetic Life Sciences Business Overview Table 110. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Sales (Kiloton), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 111. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 112. ProMetic Life Sciences Recent Development Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Alpha 1 Antitrypsin Deficiency Treatment Product Image Figure 2. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Alpha 1 Antitrypsin Deficiency Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Augmentation Therapy Image Figure 8. Cystic Fibrosis(CF) Image Figure 9. Non-CF Bronchiectasis(NCFB) Image Figure 10. Diabetes Image Figure 11. Other Image Figure 12. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type (2021-2032) Figure 15. COPD Image Figure 16. Cystic Fibrosis(CF) Image Figure 17. Non-CF Bronchiectasis(NCFB) Image Figure 18. Diabetes Image Figure 19. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application (2021-2032) Figure 22. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Alpha 1 Antitrypsin Deficiency Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. North America Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Alpha 1 Antitrypsin Deficiency Treatment Sales Value (2021-2032) & (US$ Million) Figure 31. South America Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Augmentation Therapy
  • Cystic Fibrosis(CF)
  • Non-CF Bronchiectasis(NCFB)
  • Diabetes
  • Other
Applications
  • COPD
  • Cystic Fibrosis(CF)
  • Non-CF Bronchiectasis(NCFB)
  • Diabetes
Companies covered
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Boehringer Ingelheim
  • Teva Pharmaceutical Industries
  • Takeda
  • Baxter
  • Grifols
  • CSL Behring
  • Kamada Ltd
  • Chiesi Pharmaceuticals
  • Kedrion Group
  • Vertex Pharmaceuticals
  • ProMetic Life Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics
  1. 2.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
  2. 2.2 Alpha 1 Antitrypsin Deficiency Treatment Industry Drivers
  3. 2.3 Alpha 1 Antitrypsin Deficiency Treatment Industry Opportunities and Challenges
  4. 2.4 Alpha 1 Antitrypsin Deficiency Treatment Industry Restraints
3 Alpha 1 Antitrypsin Deficiency Treatment Market by Company
  1. 3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Alpha 1 Antitrypsin Deficiency Treatment Company Ranking (2024-2026)
  4. 3.4 Global Alpha 1 Antitrypsin Deficiency Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Alpha 1 Antitrypsin Deficiency Treatment Company Product Type and Application
  6. 3.6 Global Alpha 1 Antitrypsin Deficiency Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Alpha 1 Antitrypsin Deficiency Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Alpha 1 Antitrypsin Deficiency Treatment Market by Type
  1. 4.1 Alpha 1 Antitrypsin Deficiency Treatment Type Introduction
  2. 4.1.1 Augmentation Therapy
  3. 4.1.2 Cystic Fibrosis(CF)
  4. 4.1.3 Non-CF Bronchiectasis(NCFB)
  5. 4.1.4 Diabetes
  6. 4.1.5 Other
  7. 4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Type
  8. 4.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Type (2021-2032)
  10. 4.2.3 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type (2021-2032)
5 Alpha 1 Antitrypsin Deficiency Treatment Market by Application
  1. 5.1 Alpha 1 Antitrypsin Deficiency Treatment Application Introduction
  2. 5.1.1 COPD
  3. 5.1.2 Cystic Fibrosis(CF)
  4. 5.1.3 Non-CF Bronchiectasis(NCFB)
  5. 5.1.4 Diabetes
  6. 5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Application
  7. 5.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Application (2021-2032)
  9. 5.2.3 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application (2021-2032)
6 Alpha 1 Antitrypsin Deficiency Treatment Regional Value Analysis
  1. 6.1 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Alpha 1 Antitrypsin Deficiency Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Alpha 1 Antitrypsin Deficiency Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Country, 2025 VS 2032
7 Alpha 1 Antitrypsin Deficiency Treatment Country-level Value Analysis
  1. 7.1 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Alpha 1 Antitrypsin Deficiency Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Alpha 1 Antitrypsin Deficiency Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 GlaxoSmithKline
  8. 8.2.1 GlaxoSmithKline Company Information
  9. 8.2.2 GlaxoSmithKline Business Overview
  10. 8.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  12. 8.2.5 GlaxoSmithKline Recent Developments
  13. 8.3 AstraZeneca
  14. 8.3.1 AstraZeneca Company Information
  15. 8.3.2 AstraZeneca Business Overview
  16. 8.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  18. 8.3.5 AstraZeneca Recent Developments
  19. 8.4 Boehringer Ingelheim
  20. 8.4.1 Boehringer Ingelheim Company Information
  21. 8.4.2 Boehringer Ingelheim Business Overview
  22. 8.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  24. 8.4.5 Boehringer Ingelheim Recent Developments
  25. 8.5 Teva Pharmaceutical Industries
  26. 8.5.1 Teva Pharmaceutical Industries Company Information
  27. 8.5.2 Teva Pharmaceutical Industries Business Overview
  28. 8.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  30. 8.5.5 Teva Pharmaceutical Industries Recent Developments
  31. 8.6 Takeda
  32. 8.6.1 Takeda Company Information
  33. 8.6.2 Takeda Business Overview
  34. 8.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Takeda Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  36. 8.6.5 Takeda Recent Developments
  37. 8.7 Baxter
  38. 8.7.1 Baxter Company Information
  39. 8.7.2 Baxter Business Overview
  40. 8.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Baxter Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  42. 8.7.5 Baxter Recent Developments
  43. 8.8 Grifols
  44. 8.8.1 Grifols Company Information
  45. 8.8.2 Grifols Business Overview
  46. 8.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Grifols Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  48. 8.8.5 Grifols Recent Developments
  49. 8.9 CSL Behring
  50. 8.9.1 CSL Behring Company Information
  51. 8.9.2 CSL Behring Business Overview
  52. 8.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  54. 8.9.5 CSL Behring Recent Developments
  55. 8.10 Kamada Ltd
  56. 8.10.1 Kamada Ltd Company Information
  57. 8.10.2 Kamada Ltd Business Overview
  58. 8.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  60. 8.10.5 Kamada Ltd Recent Developments
  61. 8.11 Chiesi Pharmaceuticals
  62. 8.11.1 Chiesi Pharmaceuticals Company Information
  63. 8.11.2 Chiesi Pharmaceuticals Business Overview
  64. 8.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  66. 8.11.5 Chiesi Pharmaceuticals Recent Developments
  67. 8.12 Kedrion Group
  68. 8.12.1 Kedrion Group Company Information
  69. 8.12.2 Kedrion Group Business Overview
  70. 8.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  72. 8.12.5 Kedrion Group Recent Developments
  73. 8.13 Vertex Pharmaceuticals
  74. 8.13.1 Vertex Pharmaceuticals Company Information
  75. 8.13.2 Vertex Pharmaceuticals Business Overview
  76. 8.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  78. 8.13.5 Vertex Pharmaceuticals Recent Developments
  79. 8.14 ProMetic Life Sciences
  80. 8.14.1 ProMetic Life Sciences Company Information
  81. 8.14.2 ProMetic Life Sciences Business Overview
  82. 8.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  83. 8.14.4 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  84. 8.14.5 ProMetic Life Sciences Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst